Company Overview and News

 
Why Is BlackRock Advising the ECB on the Health of EU Banks?

2018-10-16 wolfstreet
The ECB’s latest biannual stress tests are almost over. For months legions of financial regulators have been poking around in the soft financial underbellies of the Eurozone’s 130 largest banks looking for signs of weakness. Presumably, the worst causes or symptoms of financial duress have been largely sidelined or ignored, just as happened in 2016 when Spain’s then-sixth largest bank, Banco Popular, passed muster just months before its collapse.
BPESY BPESF

 
“Abusive” & Draconian Mortgages Are Creating Legal S**t Storm for Spanish Banks

2018-09-19 wolfstreet
In a somewhat unexpected move, the EU Advocate General, Maciej Szpunar, recommended that all Spanish mortgages containing a clause allowing banks to initiate foreclosure proceedings on the basis of just one missed payment is abusive and therefore should be annulled. While the EU Advocate’s ruling is not binding, in most cases it presages the ruling of the Court of Justice of the European Union (CJEU), which is expected to take place in the coming weeks.
BPESY BPESF

30
Portfolio Update For September

2018-09-14 seekingalpha
My investment goal is to grow the overall earnings per share for my portfolio - I don't even try to predict the price for my portfolio.
GIS SWK BPOP GOOGL BPESY AAPL BPESF SBUX OKE DIS DEO

 
Deutsche Bank CEO says Europe needs 'strong banks' amid merger speculation with Commerzbank

2018-08-29 cnbc
A tie-up between Germany's two biggest banks could be on the cards sooner rather than later, according to a report from the Financial Times.
BNPZY DB BPESY BNPQY BPESF BNPQF

 
The SEC Could Learn A Thing Or Two From Puerto Rico

2018-08-24 seekingalpha
Thousands of Puerto Rico residents have filed investment fraud cases against UBS, Santander, Banco Popular and Oriental.
BPESY BPESF

 
AEGON NV (AEG) CEO Alex Wynaendts on Q2 2018 Results - Earnings Call Transcript

2018-08-16 seekingalpha
Good day, and welcome to the Aegon First Half 2018 Results Conference Call. This conference is being recorded.
532540 BPESY BPESF TCS AGN TTNQY

 
Banco Santander SA (SAN) CEO José Antonio Álvarez Álvarez on Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Good morning, everyone. Thanks for joining to this First Half 2018 Grupo Santander Earnings Conference Call. As we normally do, our Group CEO will address the group performance for the first half as well as the concluding remarks. And our Group CFO will talk deeply about the different business areas' performance. And obviously, we'll have, as every quarter, plenty of time for Q&A. So without any further delay, Jose Antonio, please.
BNC BPESY BPESF SANT MS SAN

 
Banco Santander Is Much Stronger Than The Reported EPS Shows

2018-07-26 seekingalpha
This was hidden by an additional non-recurring restructuring expense related to the acquisition of Banco Popular.
BNC BPESY CTTPY BPESF SANT SAN

 
Flash - Santander posts profit fall due to Popular costs - France 24

2018-07-25 france24
Spain's banking giant Banco Santander on Wednesday posted a 3.0 percent fall in its second quarter net profit, hurt by restructuring costs and exchange rate effects.
BNC BPESY BPESF SANT SAN

 
UPDATE 1-Santander Brasil beats estimates as loan book expands

2018-07-25 reuters
SAO PAULO (Reuters) - Banco Santander Brasil SA (SANB11.SA) beat second-quarter net income estimates on Wednesday to report another three months of rapid expansion of the bank’s loan book and higher fee revenue, despite Brazil’s slow economic recovery.
BNC BPESY BPESF SANT SAN BSBR

 
UPDATE 2-Santander profits take hit from Banco Popular costs

2018-07-25 reuters
MADRID (Reuters) - Banco Santander’s (SAN.MC) net profit was hit by one-off restructuring costs from its acquisition of troubled Banco Popular, which offset otherwise solid underlying second-quarter results from Spain’s biggest bank.
BNC BPESY BPESF SANT SAN

 
Popular (BPOP) Surpasses Q2 Earnings and Revenue Estimates

2018-07-23 zacks
Popular (BPOP - Free Report) just came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.94 per share a year ago. These figures are adjusted for non-recurring items.
BPOP BPESY BPESF

 
Vemanti Group Announces Investment In eLoan, JSC

2018-07-17 globenewswire
NEWPORT BEACH, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. (OTC PINK:VMNT), a technology-driven holding company, today announced that it has entered into a definitive agreement to take 20% equity interest in eLoan, JSC (“eLoan”), a Fintech company based in Vietnam whose focus is to build a decentralized ecosystem of financial services starting with its business-centric online Peer-to-Peer (P2P) lending marketplace.
VMNT BPESY ATB BPESF

14
RPT-Several foreign funds eyeing bids for Santander property portfolio - sources

2018-07-16 reuters
MADRID, July 16 (Reuters) - Several foreign funds, among them Blackstone Group and Cerberus, are considering making bids for toxic real estate assets held by Spain’s Banco Santander, two sources with knowledge of the matter said on Monday.
BNC BGX BPESY BPESF SANT BGLF BX SAN BGB

14
Several foreign funds eyeing bids for Santander property portfolio - sources

2018-07-16 reuters
MADRID, July 16 (Reuters) - Several foreign funds, among them Blackstone Group and Cerberus, are considering making bids for toxic real estate assets held by Spain’s Banco Santander, two sources with knowledge of the matter said on Monday.
BNC BGX BPESY BPESF SANT BGLF BX SAN BGB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...